- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - mnc pharma
- NOVARTIS - DR. DATSONS LABS
NOVARTIS vs DR. DATSONS LABS - Comparison Results
Current Valuations
| NOVARTIS | DR. DATSONS LABS | NOVARTIS/ DR. DATSONS LABS |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 377.6 | -10.9 | - | View Chart |
| P/BV | x | 30.2 | 0.2 | 18,611.2% | View Chart |
| Dividend Yield | % | 1.5 | 0.0 | - |
Financials
 NOVARTIS  DR. DATSONS LABS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| NOVARTIS Mar-18 |
DR. DATSONS LABS Mar-14 |
NOVARTIS/ DR. DATSONS LABS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 758 | 126 | 603.5% | |
| Low | Rs | 579 | 31 | 1,873.8% | |
| Sales per share (Unadj.) | Rs | 228.4 | 133.0 | 171.7% | |
| Earnings per share (Unadj.) | Rs | 31.7 | 0.2 | 20,933.6% | |
| Cash flow per share (Unadj.) | Rs | 32.8 | 6.6 | 495.8% | |
| Dividends per share (Unadj.) | Rs | 10.00 | 0 | - | |
| Dividend yield (eoy) | % | 1.5 | 0 | - | |
| Book value per share (Unadj.) | Rs | 297.1 | 128.8 | 230.7% | |
| Shares outstanding (eoy) | m | 24.69 | 31.66 | 78.0% | |
| Bonus/Rights/Conversions | - | FCCB | - | ||
| Price / Sales ratio | x | 2.9 | 0.6 | 497.5% | |
| Avg P/E ratio | x | 21.1 | 516.1 | 4.1% | |
| P/CF ratio (eoy) | x | 20.4 | 11.8 | 172.3% | |
| Price / Book Value ratio | x | 2.2 | 0.6 | 370.3% | |
| Dividend payout | % | 31.5 | 0 | - | |
| Avg Mkt Cap | Rs m | 16,505 | 2,477 | 666.2% | |
| No. of employees | `000 | 0.7 | NA | - | |
| Total wages/salary | Rs m | 1,445 | 56 | 2,580.9% | |
| Avg. sales/employee | Rs Th | 8,441.3 | NM | - | |
| Avg. wages/employee | Rs Th | 2,163.6 | NM | - | |
| Avg. net profit/employee | Rs Th | 1,173.1 | NM | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,639 | 4,211 | 133.9% | |
| Other income | Rs m | 1,718 | 79 | 2,183.4% | |
| Total revenues | Rs m | 7,357 | 4,289 | 171.5% | |
| Gross profit | Rs m | -63 | 569 | -11.0% | |
| Depreciation | Rs m | 25 | 204 | 12.4% | |
| Interest | Rs m | 55 | 430 | 12.9% | |
| Profit before tax | Rs m | 1,575 | 13 | 12,403.1% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | -2 | 0.0% | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 792 | 6 | 12,977.0% | |
| Profit after tax | Rs m | 784 | 5 | 16,325.0% | |
| Gross profit margin | % | -1.1 | 13.5 | -8.2% | |
| Effective tax rate | % | 50.3 | 48.0 | 104.6% | |
| Net profit margin | % | 13.9 | 0.1 | 12,189.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 9,522 | 6,852 | 139.0% | |
| Current liabilities | Rs m | 3,296 | 6,711 | 49.1% | |
| Net working cap to sales | % | 110.4 | 3.3 | 3,296.9% | |
| Current ratio | x | 2.9 | 1.0 | 282.9% | |
| Inventory Days | Days | 37 | 161 | 22.8% | |
| Debtors Days | Days | 28 | 318 | 8.9% | |
| Net fixed assets | Rs m | 46 | 3,673 | 1.3% | |
| Share capital | Rs m | 123 | 317 | 39.0% | |
| "Free" reserves | Rs m | 7,213 | 3,761 | 191.8% | |
| Net worth | Rs m | 7,336 | 4,078 | 179.9% | |
| Long term debt | Rs m | 0 | 1,671 | 0.0% | |
| Total assets | Rs m | 11,105 | 12,633 | 87.9% | |
| Interest coverage | x | 29.5 | 1.0 | 2,863.9% | |
| Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
| Sales to assets ratio | x | 0.5 | 0.3 | 152.3% | |
| Return on assets | % | 7.6 | 3.4 | 219.4% | |
| Return on equity | % | 10.7 | 0.1 | 9,073.3% | |
| Return on capital | % | 22.2 | 7.7 | 289.6% | |
| Exports to sales | % | 0 | 22.9 | 0.0% | |
| Imports to sales | % | 0 | 14.3 | 0.0% | |
| Exports (fob) | Rs m | NA | 964 | 0.0% | |
| Imports (cif) | Rs m | NA | 602 | 0.0% | |
| Fx inflow | Rs m | 61 | 964 | 6.3% | |
| Fx outflow | Rs m | 3,630 | 607 | 598.0% | |
| Net fx | Rs m | -3,570 | 357 | -1,000.2% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,610 | 1,345 | 119.7% | |
| From Investments | Rs m | 687 | -2,256 | -30.5% | |
| From Financial Activity | Rs m | -2,677 | -1,200 | 223.1% | |
| Net Cashflow | Rs m | -380 | -2,111 | 18.0% | |
Share Holding
| Indian Promoters | % | 0.0 | 4.5 | - | |
| Foreign collaborators | % | 75.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 2.0 | 0.0 | - | |
| FIIs | % | 1.6 | 1.4 | 118.5% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 21.5 | 94.1 | 22.8% | |
| Shareholders | 41,647 | 20,807 | 200.2% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare NOVARTIS With: PLETHICO PHARMA BIOCON LTD J.B.CHEMICALS NATCO PHARMA DIVIS LABORATORIES
Compare NOVARTIS With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
US-China Trade Talks, Oil Prices, and Top Stocks in Action Today(Pre-Open)
On Tuesday, share markets in India witnessed selling pressure during closing hours and ended their trading session marginally lower after a volatile day of trading.
Related Views on News
NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)
Nov 21, 2018 | Updated on Nov 21, 2018For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)
Jul 30, 2018 | Updated on Jul 30, 2018For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)
Jul 20, 2018 | Updated on Jul 20, 2018For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)
Feb 7, 2019Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)
Feb 8, 2019This is the trick to following super investors and not losing money.
Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)
Feb 14, 2019Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)
Feb 14, 2019During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
More|
| |
NOVARTIS SHARE PRICE
Feb 19, 2019 (Close)
TRACK NOVARTIS
- Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON NOVARTIS
NOVARTIS 5-YR ANALYSIS
COMPARE NOVARTIS WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.